Company profile
MediWound Ltd.
NASDAQ:MDWDMedicinal Chemicals and Botanical Products
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| STEM BROMELAIN | phase3 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06568627 | phase3 | recruiting | 2025-06-01 | 2026-12-01 | MediWound Ltd | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) |
| NCT04817228 | phase2 | completed | 2021-04-21 | 2022-05-06 | MediWound Ltd | A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers |
| NCT02278718 | phase3 | completed | 2015-05-01 | 2021-04-01 | MediWound Ltd | A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care |
| NCT02148705 | phase3 | completed | 2015-05-27 | 2018-06-12 | MediWound Ltd | A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns |
| NCT05157763 | phase1_2 | recruiting | 2021-06-30 | 2022-05-01 | MediWound Ltd | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma |
FDA applications (0)
No records yet.